Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
BLIMP-1 and CD39 expression define human effector memory regulatory T cells in blood and recall responses to viruses. [PDF]
Phetsouphanh C +10 more
europepmc +1 more source
Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity. [PDF]
Bockman A +8 more
europepmc +1 more source
HDCA suppresses exosomal lncRNA MSTRG171708 release to inhibit Treg-mediated immunometabolism in hepatocellular carcinoma. [PDF]
Yang F +10 more
europepmc +1 more source
CAR-T cells and CAR-Treg cells for treatment of inflammatory bowel diseases. [PDF]
Neurath MF.
europepmc +1 more source
Endogenous Amphiregulin promotes muscle repair and function through expansion of fibro-adipogenic progenitors during chronic <i>Toxoplasma gondii</i> infection in mice. [PDF]
Shihab R +4 more
europepmc +1 more source
CD47 and FOXP3<sup>+</sup> Regulatory Immunity in Colorectal Cancer: A Conceptual Framework for Coordinated Immunosuppression. [PDF]
Li Q +7 more
europepmc +1 more source
Tregs in transplantation tolerance: role and therapeutic potential [PDF]
CD4+ Foxp3+ regulatory T cells (Tregs) are indispensable for preventing autoimmunity, and they play a role in cancer and transplantation settings by restraining immune responses.
Maria-Luisa Alegre +2 more
exaly +2 more sources

